Previous Close | 56.38 |
Open | 56.34 |
Bid | 56.70 x 0 |
Ask | 56.72 x 0 |
Day's Range | 56.28 - 56.94 |
52 Week Range | 44.39 - 58.14 |
Volume | |
Avg. Volume | 606,896 |
Market Cap | 63.288B |
Beta (5Y Monthly) | 0.73 |
PE Ratio (TTM) | 42.01 |
EPS (TTM) | 1.35 |
Earnings Date | May 07, 2024 |
Forward Dividend & Yield | 0.95 (1.68%) |
Ex-Dividend Date | Apr 19, 2024 |
1y Target Est | 59.10 |
Subscribe to Yahoo Finance Plus to view Fair Value for SHL.DE
Dutch healthcare-equipment maker [Royal Philips just announced a long-awaited deal with U.S. authorities](https://www.wsj.com/business/retail/philips-reaches-agreement-with-fda-over-ventilator-recall-90242fd9) over its scandal-struck sleep-apnea machines. The explanation is that the settlement didn’t bring the kind of clarity on the future of Philips’ respiratory business that investors might have hoped for. Under the terms of a provisional agreement with the Food and Drug Administration, it won’t be allowed to sell its sleep-apnea machines in the U.S. until it meets undisclosed requirements.
TARRYTOWN, N.Y., July 20, 2023--The newest addition to the Siemens Healthineers Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer1 for immunoassay and clinical chemistry testing, has received FDA clearance and is now available in many of the world’s major markets. Labs operating at low to medium testing volumes will benefit from competitive advantages that the analyzer offers, including improved turnaround time predictability, advanced reporting functionality, and focused safety
RS Abdi Waluyo located in Jakarta will be the first hospital in Indonesia to acquire the NAEOTOM Alpha, the world's first photon-counting CT with the aim to optimise diagnostic and treatment pathways for patients in the country.